Loading...
Market
What will be the next major milestone for UP421 by September 30, 2025?
2
Resolution / Starting Odds
Phase 2 trial initiation • 25%
Partnership with healthcare provider • 25%
Regulatory approval application • 25%
Other milestone • 25%
Company announcements or press releases
Story
Sana's UP421 Therapy Shows Breakthrough in Type 1 Diabetes; Stock Surges 300%
Jan 7, 2025, 11:12 PM
Sana Biotechnology has announced promising initial results from a first-in-human, investigator-sponsored study involving its hypoimmune (HIP)-engineered islet cell therapy, UP421, for type 1 diabetes. Conducted in partnership with Uppsala University Hospital, the therapy demonstrated the ability to evade immune rejection and produce insulin without the need for immunosuppression. The study showed graft survival at 28 days, with evidence of functional pancreatic beta cells producing insulin, as indicated by circulating C-peptide levels, which increased during a mixed meal tolerance test. MRI scans confirmed the survival of the transplanted cells. The study identified no safety concerns and marks a potential breakthrough in treating type 1 diabetes. Sana's stock surged significantly, gaining over 300% in after-hours trading, with the company adding approximately $900 million to its market capitalization. The therapy, if successful in further trials, could offer a scalable, curative treatment for type 1 diabetes, eliminating the need for insulin injections or immunosuppressive drugs.
View original story
Similar markets
Phase 3 trial completion • 25%
Regulatory approval • 25%
Commercial launch • 25%
Partnership or acquisition • 25%
Initiation of Phase 4 trial • 25%
Launch of a new indication study • 25%
No major milestone announced • 25%
Regulatory approval in Europe • 25%
New payload announcement • 25%
Second static fire test • 25%
Partnership announcement • 25%
Second orbital launch • 25%
Phase 1 completion • 25%
No significant milestone • 25%
Phase 3 completion • 25%
Phase 2 completion • 25%
Logistical issues • 25%
Public protests • 25%
Staffing shortages • 25%
Legal challenges • 25%
New Funding Round • 25%
Rocket Launch • 25%
Partnership Announcement • 25%
Other • 25%
Certification for regular missions • 25%
Successful uncrewed test flight • 25%
Successful crewed test flight • 25%
No major milestone achieved • 25%
Raqqa City • 25%
Tabqa Dam • 25%
Deir ez-Zor • 25%
Other • 25%
Mission failure or withdrawal • 25%
Deterioration in security • 25%
Status quo maintained • 25%
Improved security in Somalia • 25%
First Major Funding Round • 25%
Completion of Site Preparation • 25%
Start of Construction • 25%
Partnership with New Stakeholders • 25%
New all-time high market cap • 25%
Other milestone • 25%
Major acquisition or merger • 25%
Launch of a new vehicle model • 25%